Abstract: Stroke is a significant leading cause of death and disability in the United States (Tsao et al., 2022). Approximately 87% of strokes fall into the ischemic category, mainly caused by arterial blockage (Jayaraj et al., 2019). Although the only FDA-approved effective medication is tissue plasminogen activator (tPA), it should be administrated within 4.5 hours of ischemic stroke. Furthermore, tPA has been an integral part of managing acute ischemic stroke. However, it increases the development of intracerebral hemorrhage (Goncalves et al., 2022). Therefore, discovering a novel neuroprotective drug is a high clinical need. In recent years, there has been a significant increase in the utilization of thrombectomy procedures.